Cylert
Cylert Uses, Dosage, Side Effects, Food Interaction and all others data.
In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.
Cylert belongs to the group of medicines called central nervous system (CNS) stimulants. It is used to treat attention deficit hyperactivity disorder (ADHD). Cylert stimulates the brain, probably by affecting neurotransmitters, the chemicals in the brain that nerves use to communicate with each other.
| Trade Name | Cylert |
| Availability | Discontinued |
| Generic | Pemoline |
| Pemoline Other Names | pemolina, Pemoline |
| Related Drugs | Adderall, Vyvanse, methylphenidate, Concerta, Strattera, Ritalin |
| Type | Oral |
| Formula | C9H8N2O2 |
| Weight | Average: 176.172 Monoisotopic: 176.05857751 |
| Protein binding | Approximately 50% (bound to plasma proteins). |
| Groups | Approved, Illicit, Investigational, Withdrawn |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Cylert is a central nervous system (CNS) stimulant that was previously used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy.
For treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Toxicity
Side effects include insomnia, anorexia, stomach ache, skin rashes, increased irritability, mild depression, nausea, dizziness, headache, drowsiness, and hallucinations
Food Interaction
- Avoid alcohol.
- Limit caffeine intake.
- Take with or without food. Food does not significantly affect absorption.
Cylert Hypertension interaction
[Major] The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.
Sudden death has been reported in adults and children taking CNS stimulant treatment.
Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.
A careful assessment of the cardiovascular status should be done in patients being considered for treatment.
This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).
Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.
Hypertension interaction[Major] CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.
Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.
All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.
Cylert Drug Interaction
Moderate: interferon beta-1b, interferon beta-1b, tiagabine, tiagabineUnknown: amoxicillin / clavulanate, amoxicillin / clavulanate, multivitamin, multivitamin, citalopram, citalopram, glatiramer, glatiramer, isopropyl alcohol topical, isopropyl alcohol topical, glucose, glucose, selegiline, selegiline, fluticasone nasal, fluticasone nasal
Elimination Route
Cylert is rapidly absorbed from the gastrointestinal tract
Half Life
The serum half-life of pemoline is approximately 12 hours.
Elimination Route
Cylert is excreted primarily by the kidneys with approximately 50% excreted unchanged and only minor fractions present as metabolites.
Innovators Monograph
You find simplified version here Cylert
